RxDoctor Payments Data

Jorge de Jesus Miranda, MD

Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1376630202

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Johnson & Johnson at 45.1% of the total. Reporting peaked in 2019 at $17,421 and has fallen 93.0% since, to $1,227 in 2025. Among endocrinology, diabetes & metabolism clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,988in general payments, 2019–2025

Across 275 payments — averaging $109.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$14K
  • Sanofi-aventis U.S. LLC$6K
  • AbbVie$4K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$764
  • plus $3K from 15 others

What the payments were for

  • Consulting fees$4,07514%
  • Speaking & faculty fees$16,41655%
  • Food & beverage$9,35731%
  • Education$1400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson32$13,537
Sanofi-aventis U.S. LLC26$5,711
AbbVie11$4,016
AstraZeneca49$1,385
Novo Nordisk50$1,356
Boehringer Ingelheim21$764
Bayer10$466
Amgen6$408
Merck6$399
Bayer Puerto Rico Inc.19$396
Abbott15$362
Dexcom, Inc.9$347
Eli Lilly Export S.A. Puerto Rico Branch9$210
Valeritas, Inc.1$187
Lilly USA, LLC1$120
Medtronic2$109
PBG Puerto Rico LLC4$81
Radius Health, Inc.1$50
Sanofi1$43
Novartis1$20
Pfizer Pharmaceuticals LLC1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,988 in reported general payments places this provider in the 90th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$40,372
Medicare patients
133
Services billed
362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide832$835,652
OzempicSemaglutide534$546,841
JardianceEmpagliflozin473$403,388
FarxigaDapagliflozin Propanediol259$182,378
TradjentaLinagliptin220$152,169
SynthroidLevothyroxine Sodium1,222$132,810
RybelsusSemaglutide124$124,847
JanuviaSitagliptin Phosphate94$98,477
MounjaroTirzepatide76$79,814
LantusInsulin Glargine,hum.Rec.Anlog564$48,516
Janumet XrSitagliptin Phos/Metformin Hcl58$47,466
Trijardy XrEmpaglifloz/Linaglip/Metformin25$25,457
Synjardy XrEmpagliflozin/Metformin Hcl32$23,616
GlyxambiEmpagliflozin/Linagliptin26$23,218
JanumetSitagliptin Phos/Metformin Hcl28$22,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Humalog Mix 75-25$120$949,9731,280 claims
Novo NordiskOzempic, Rybelsus$1,356$671,688658 claims
Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Synjardy Xr, Glyxambi$764$647,014801 claims
AstraZenecaFarxiga$1,385$182,378259 claims
MerckJanuvia, Janumet Xr, Janumet$399$168,311180 claims
AbbVieSynthroid, Creon$4,016$140,9751,233 claims
Sanofi-aventis U.S. LLCLantus$5,711$48,516564 claims
AmgenProlia$408$21,51512 claims
Johnson & JohnsonInvokana$13,537$11,88414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →